يعرض 1 - 10 نتائج من 13 نتيجة بحث عن '"Kurt Marhardt"', وقت الاستعلام: 0.89s تنقيح النتائج
  1. 1
    دورية أكاديمية
    Effectiveness, Healthcare Resource Utilization and Adherence to Subcutaneous Interferon Beta-1a According to Age in Patients With Multiple Sclerosis: A Cohort Study Using a US Claims Database

    المؤلفون: Arthur Allignol, Emmanuelle Boutmy, Meritxell Sabidó Espin, Kurt Marhardt, Patrick Vermersch

    المصدر: Frontiers in Neurology, Vol 12 (2021)

    مصطلحات موضوعية: adherence, age, healthcare utilization, subcutaneous interferon beta-1a, multiple sclerosis, relapse, Neurology. Diseases of the nervous system, RC346-429

    وصف الملف: electronic resource

    Relation: https://www.frontiersin.org/articles/10.3389/fneur.2021.676585/full; https://doaj.org/toc/1664-2295

    URL الوصول: https://doaj.org/article/a3075d9deb9e42a3bd8377d2afbc1c8d

    Full Text Finder
    أضف إلى المفضلة
  2. 2
    Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon β-1a

    المؤلفون: Kurt Marhardt, Joost Smolders, Frederik Barkhof, Manolo Beelke, Luigi M E Grimaldi, Myriam Schluep, Raymond Hupperts, Joep Killestein, Trygve Holmøy, Reinhold Vieth

    المساهمون: Neurology, AII - Inflammatory diseases, Radiology and nuclear medicine, Amsterdam Neuroscience - Neurodegeneration, Klinische Neurowetenschappen, MUMC+: MA Med Staf Spec Neurologie (9), RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience

    المصدر: Neurology, 93(20), e1906-e1916. Lippincott Williams and Wilkins
    Neurology, 93(20), E1906-E1916. LIPPINCOTT WILLIAMS & WILKINS
    Hupperts, R, Smolders, J, Vieth, R, Holmøy, T, Marhardt, K, Schluep, M, Killestein, J, Barkhof, F, Beelke, M, Grimaldi, L M E & SOLAR Study Group 2019, ' Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon β-1a ', Neurology, vol. 93, no. 20, pp. e1906-e1916 . https://doi.org/10.1212/WNL.0000000000008445
    Neurology

    مصطلحات موضوعية: Male, 25-HYDROXYVITAMIN D, MULTICENTER, PROGRESSION, Rate ratio, Gastroenterology, law.invention, SUPPLEMENTATION, chemistry.chemical_compound, DOUBLE-BLIND, 0302 clinical medicine, Randomized controlled trial, law, CHOLECALCIFEROL, 030212 general & internal medicine, Vitamin D, RISK, Brain, Vitamins, Magnetic Resonance Imaging, Treatment Outcome, SAFETY, MULTIPLE-SCLEROSIS ACTIVITY, Drug Therapy, Combination, Female, Interferon beta-1a, Adult, Vitamin, medicine.medical_specialty, Placebo, Article, CALCIUM, 03 medical and health sciences, Multiple Sclerosis, Relapsing-Remitting, Adjuvants, Immunologic, Double-Blind Method, Internal medicine, medicine, Humans, business.industry, Odds ratio, Confidence interval, Clinical trial, chemistry, Neurology (clinical), Cholecalciferol, business, 030217 neurology & neurosurgery

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9063d4c32d25ce334cdcf54e7709fe1c
    https://cris.maastrichtuniversity.nl/en/publications/1806879e-3b94-4053-a781-52c1786c9b08

    أضف إلى المفضلة
  3. 3
    Effectiveness, Healthcare Resource Utilization and Adherence to Subcutaneous Interferon Beta-1a According to Age in Patients With Multiple Sclerosis: A Cohort Study Using a US Claims Database

    المؤلفون: Patrick Vermersch, Emmanuelle Boutmy, Arthur Allignol, Meritxell Sabido Espin, Kurt Marhardt

    المصدر: Frontiers in Neurology, Vol 12 (2021)
    Frontiers in Neurology

    مصطلحات موضوعية: medicine.medical_specialty, subcutaneous interferon beta-1a, multiple sclerosis, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Health care, medicine, adherence, 030212 general & internal medicine, Claims database, Medical prescription, RC346-429, Original Research, relapse, business.industry, Multiple sclerosis, Interferon beta-1a, healthcare utilization, medicine.disease, Discontinuation, age, Neurology, Healthcare utilization, Neurology. Diseases of the nervous system, Neurology (clinical), business, 030217 neurology & neurosurgery, Cohort study, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11a8480c1d95f0b0742284a8c158fa6a
    https://pubmed.ncbi.nlm.nih.gov/34381411

    أضف إلى المفضلة
  4. 4
    MAGNIMS score predicts long-term clinical disease activity-free status and confirmed disability progression in patients treated with subcutaneous interferon beta-1a

    المؤلفون: Maria Pia Sormani, Nicola De Stefano, Ludwig Kappos, Julie Aldridge, Mark S. Freedman, Kurt Marhardt

    مصطلحات موضوعية: Clinical disease activity, Disability progression, Interferon beta-1a, MAGNIMS, Predictor of disease progression, Scoring system, medicine.medical_specialty, Multiple Sclerosis, Injections, Subcutaneous, Relapsing-Remitting, Gastroenterology, Injections, Disease Progression, Humans, Interferon-beta, Magnetic Resonance Imaging, Recurrence, Treatment Outcome, Multiple Sclerosis, Relapsing-Remitting, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, In patient, 030212 general & internal medicine, medicine.diagnostic_test, business.industry, Subcutaneous, Multiple sclerosis, Hazard ratio, Magnetic resonance imaging, General Medicine, medicine.disease, Clinical disease, Confidence interval, Neurology, Neurology (clinical), business, 030217 neurology & neurosurgery, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5096b8fac1a88a4b420f0b8df7b5d041
    http://hdl.handle.net/11365/1127379

    أضف إلى المفضلة
  5. 5
    L’interféron bêta-1a sous-cutané 22/44 μg démontre une efficacité comparable à celle du tériflunomide chez les patients atteints de sclérose en plaques nouvellement traités – Étude menée avec l’Observatoire français de la sclérose en plaques (OFSEP)

    المؤلفون: David-Axel Laplaud, Emmanuelle Boutmy, Caroline Foch, Fabien Rollot, Kurt Marhardt, Meritxell Sabidó

    المصدر: Revue Neurologique. 176:S79-S80

    مصطلحات موضوعية: Neurology, Neurology (clinical)

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::bce7c7db9d4a5b680d98be8fcc662949
    https://doi.org/10.1016/j.neurol.2020.01.239

    View record from ScienceDirect
    أضف إلى المفضلة
  6. 6
    No evidence of disease activity status in patients treated with early vs. delayed subcutaneous interferon β-1a

    المؤلفون: Patricia K. Coyle, Ludwig Kappos, Julie Aldridge, Kurt Marhardt, Mark S. Freedman, Giancarlo Comi, Liang Chen

    المصدر: Multiple Sclerosis and Related Disorders. 39:101891

    مصطلحات موضوعية: medicine.medical_specialty, education.field_of_study, Clinically isolated syndrome, business.industry, Population, General Medicine, Placebo, Gastroenterology, Disease activity, 03 medical and health sciences, Interferon β 1a, Regimen, 0302 clinical medicine, Neurology, Internal medicine, Medicine, In patient, 030212 general & internal medicine, Neurology (clinical), Dosing, business, education, 030217 neurology & neurosurgery

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49774c729dbcb82123b39361bd52d247
    https://doi.org/10.1016/j.msard.2019.101891

    View record from ScienceDirect Full Text via ClinicalKey
    أضف إلى المفضلة
  7. 7
    Corrigendum to 'Subcutaneous interferon beta-1a 22/44 µg demonstrates comparable effectiveness versus teriflunomide in newly treated patients with multiple sclerosis. A study in a French nationwide cohort of Multiple Sclerosis: Observatoire Francais de la sclérose en plaques' [Multiple Sclerosis and Related Disorders, 37 (2020) 101598]

    المؤلفون: Fabien Rollot, David Laplaud, Meritxell Sabidó, Emmanuelle Boutmy, Kurt Marhardt, Caroline Foch

    المصدر: Multiple Sclerosis and Related Disorders. :102087

    مصطلحات موضوعية: Oncology, medicine.medical_specialty, business.industry, Multiple sclerosis, Interferon beta-1a, General Medicine, medicine.disease, chemistry.chemical_compound, Neurology, chemistry, Internal medicine, Cohort, Teriflunomide, medicine, Neurology (clinical), business, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::d0bae700136f3798556432f2191d4efd
    https://doi.org/10.1016/j.msard.2020.102087

    View record from ScienceDirect Full Text via ClinicalKey
    أضف إلى المفضلة
  8. 8
    Subcutaneous Interferon Beta-1a 22/44 mg Demonstrates Comparable Effectiveness Versus Teriflunomide in Newly Treated Patients with Multiple Sclerosis. a Study in a French Nationwide Cohort of Multiple Sclerosis: Observatoire Francais De La Sclérose En Pla

    المؤلفون: Emmanuelle Boutmy, David Laplaud, Fabien Rollot, Meritxell Sabidó, Caroline Foch, Kurt Marhardt

    المصدر: Multiple Sclerosis and Related Disorders. 37:101598

    مصطلحات موضوعية: Oncology, medicine.medical_specialty, business.industry, Multiple sclerosis, Interferon beta-1a, General Medicine, medicine.disease, chemistry.chemical_compound, Neurology, chemistry, Internal medicine, Teriflunomide, Cohort, Medicine, Neurology (clinical), business, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::6727fa7da9ea5d6610ec46360e332951
    https://doi.org/10.1016/j.msard.2019.11.073

    View record from ScienceDirect Full Text via ClinicalKey
    أضف إلى المفضلة
  9. 9
    Magnetic Resonance Imaging in Multiple Sclerosis (MAGNIMS) Score Predicts Long-term Clinical Disease Activity (CDA)-free Status and Disability Progression in Subcutaneous Interferon Beta-1a (scifnβ-1a)-treated Patients

    المؤلفون: M. P. Sormani, Kurt Marhardt, N. De Stefano, Mark S. Freedman, Julie Aldridge

    المصدر: Multiple Sclerosis and Related Disorders. 26:240-241

    مصطلحات موضوعية: Oncology, medicine.medical_specialty, medicine.diagnostic_test, business.industry, Multiple sclerosis, Interferon beta-1a, Magnetic resonance imaging, General Medicine, Clinical disease, medicine.disease, Term (time), Neurology, Internal medicine, medicine, Disability progression, Neurology (clinical), business, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::740c12f41b00989a189aa98755dfa578
    https://doi.org/10.1016/j.msard.2018.10.037

    View record from ScienceDirect Full Text via ClinicalKey
    أضف إلى المفضلة
  10. 10
    Impact of Gadolinium-enhancing (GD+) Lesions on No Evidence of Disease Activity (NEDA) Status in Subcutaneous Interferon Beta-1a (SC IFNβ-1a)-treated Patients

    المؤلفون: G. Comi, Julie Aldridge, Kurt Marhardt, L Kappos, Mark S. Freedman, Patricia K. Coyle

    المصدر: Multiple Sclerosis and Related Disorders. 26:239-240

    مصطلحات موضوعية: medicine.medical_specialty, business.industry, Multiple sclerosis, Gadolinium, Interferon beta-1a, chemistry.chemical_element, General Medicine, medicine.disease, Gastroenterology, Disease activity, Neurology, chemistry, Internal medicine, medicine, Neurology (clinical), business, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::4a640a993b8df2bccfc318c3b9123d54
    https://doi.org/10.1016/j.msard.2018.10.035

    View record from ScienceDirect Full Text via ClinicalKey
    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء